AU2016327484B2 - Inhaling fragrance, perfume, and food flavoring - Google Patents
Inhaling fragrance, perfume, and food flavoring Download PDFInfo
- Publication number
- AU2016327484B2 AU2016327484B2 AU2016327484A AU2016327484A AU2016327484B2 AU 2016327484 B2 AU2016327484 B2 AU 2016327484B2 AU 2016327484 A AU2016327484 A AU 2016327484A AU 2016327484 A AU2016327484 A AU 2016327484A AU 2016327484 B2 AU2016327484 B2 AU 2016327484B2
- Authority
- AU
- Australia
- Prior art keywords
- fragrance
- inhalation
- mass
- amount
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/40—Tea flavour; Tea oil; Flavouring of tea or tea extract
- A23F3/42—Isolation or recuperation of tea flavour or tea oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Tea And Coffee (AREA)
- Seasonings (AREA)
- Cosmetics (AREA)
Abstract
[Problem] To provide an inhaling fragrance that can be taken in other than through oral administration. [Solution] The inhaling fragrance includes leaf alcohol and linalool, includes ethanol as a primary solvent, and is liquid at normal temperature. The leaf alcohol is included in an amount of 0.02% by mass to 0.5% by mass with respect to the total amount and the linalool is included in an amount of 0.005% by mass to 0.1% by mass with respect to the total amount. When taken in through inhalation, the inhaling fragrance exhibits any one or more of an anti-oxidant effect against oxidative stress due to aging and an anti-oxidant effect against oxidative stress due to radiation. When taken in through inhalation, the inhaling fragrance exhibits an anti-mental stress effect.
Description
INHALING FRAGRANCE, PERFUME, AND FOOD FLAVORING
Technical Field [0001]
The present invention relates to an inhalation fragrance having an antioxidant action.
Background Art [0002]
Oxidation of substances constituting animal bodies causes physical deconditioning, onset of disease, and acceleration of aging. Accordingly, it is desirable to take in substances that have an antioxidant action, that is, an action of suppressing oxidation. It has hitherto been known that some familiar luxury grocery items, for example, green tea, have antioxidant actions and antiaging actions (for example, PTL 1).
[0003]
However, it is difficult in practice to orally take in an effective amount. While the antioxidant mechanism upon the oral intake has not been elucidated, the amounts of active ingredients absorbed from the intestinal tract are significantly less as compared with the intake and it is necessary to take in a considerably large amount in order to get a desired effect.
[0004]
On the other hand, it is known that a green tea extract has a mental sedation effect when used as a fragrance (for example, PTL 2).
[0005]
However, any antioxidatively effective inhalation fragrance having a green tea component incorporated has not been known.
Citation List
Patent Literature [0006]
PTL 1: JP-A-2004-2237
PTL 2: Japanese Patent No. 5306160
Summary of Invention
Technical Problem [0007]
A problem to be solved by the invention is to provide an inhalation fragrance that can be taken in by means other than oral administration.
Solution to Problem [0008]
The inhalation fragrance according to the present invention for solving the above problem is a liquid inhalation fragrance that contains leaf alcohol and linalool, and contains ethanol as a main solvent.
Advantageous Effect of Invention [0009]
The present invention can provide an inhalation fragrance that can be taken in by means other than oral administration .
Brief Description of Drawings [0010] [Fig. 1] Fig. 1 is an external view of a metabolic cage.
[Fig. 2] Fig. 2 is a graph showing amounts of 8-OHdG in urine associated with aging in Experiment 1.
[Fig. 3] Fig. 3 is a graph showing amounts of 8-OHdG in urine associated with exposure to radiation in Experiment 2.
[Fig. 4] Fig. 4 is a graph showing the change in amount of water drunk with time in Experiment 3.
[Fig. 5] Fig. 5 is a graph showing amounts of 8-OHdG in urine associated with aging in Experiment 4.
[Fig. 6] Fig. 6 is a graph showing amounts of 8-OHdG in urine associated with exposure to radiation in Experiment 5.
[Fig. 7] Fig. 7 is a graph showing measurement results of antioxidant capacity in serum in Experiment 6.
Description of Embodiments [0011]
An inhalation fragrance, a perfume, and a food according to one embodiment of the present invention will be described with reference to drawings.
[0012]
The inhalation fragrance of the present embodiment contains leaf alcohol and linalool as active ingredients. The inhalation fragrance may further contain other active ingredients, such as benzyl alcohol, and impurities. The inhalation fragrance is liquid at normal temperature (18°C to 25°C) . The main solvent of the inhalation fragrance may be ethanol. Accordingly, when the inhalation fragrance is heated to the temperature being in the vicinity of 35°C to 37°C, which almost correspond to human body temperature, leaf alcohol and linalool as active ingredients evaporate and thereby can be inhaled by humans and animals. The inhalation fragrance gradually evaporates even at normal temperature and can be inhaled by humans and animals.
[0013]
Leaf alcohol, which is another name of cis-3-hexen-l-ol and is also called hexenol, is a substance contained in tea leaves. The leaf alcohol may contain isomers. Ethanol is a good solvent for leaf alcohol.
[0014]
Linalool, which refers to
3,7-dimethyl-l,6-octadien-3-ol, is a substance contained in tea leaves. Ethanol is a good solvent for linalool.
[0015]
As a desired formulation, the inhalation fragrance contains leaf alcohol in an amount of 0.02% by mass or more and 0.5% by mass or less and linalool in an amount of 0.005% by mass or more and 0.1% by mass or less based on the total amount. The balance may be ethanol and water. In this case, for example, ethanol may account for 99.9% by mass with the balance being water.
[0016]
The effects of the inhalation fragrance remain even if the inhalation fragrance contains impurities, other fragrances, surfactants, colorants, and the like. The impurities, as used herein, mean substances that have almost no influence on the effects of the inhalation fragrance if contained in the inhalation fragrance. Some impurities are desirably contained in the inhalation fragrance.
[0017]
The inhalation fragrance having the above composition has a fragrance and when taken in by humans and animals through inhalation, the inhalation fragrance has an antioxidant action. Antioxidant actions include an antioxidant action against oxidation due to aging and an antioxidant action against radiation exposure stress.
[0018]
Leaf alcohol, which is one of active ingredients of the inhalation fragrance, has heretofore been discarded in the form of vapor in the step of steaming in tea manufacture. Accordingly, manufactured tea products, such as green tea, contain little leaf alcohol.
[0019]
In contrast, the inhalation fragrance of the present embodiment can be produced by collecting steam obtained in steaming of raw tea leaves and concentrating the steam by distillation. Accordingly, the inhalation fragrance is rich in leaf alcohol and linalool as compared with the manufactured tea products. When the inhalation fragrance of the present embodiment is taken in through inhalation, leaf alcohol and linalool can be more efficiently taken in than when a manufactured tea product, such as a green tea, is orally taken in through hot water extraction. Thus, the inhalation fragrance can provide an antioxidant action against oxidation due to aging and an antioxidant action against radiation exposure stress which are difficult to get only by oral intake of green tea.
[0020]
The mechanism has not been fully elucidated for the antioxidant action against oxidation due to aging and the antioxidant action against radiation exposure stress in humans and animals, such as mouse, exhibited by leaf alcohol and linalool. In experiments, an anti-mental stress action such as a high relaxation effect has been confirmed: for example, amounts of water drunk by mice were significantly less in an administrated group than in a control group.
[0021]
The inhalation fragrance may be used as it is, or as a perfume containing the other fragrance, a surfactant, and a colorant. The perfume does not lose the antioxidant action and the anti-mental stress action as mentioned above even when containing the other fragrances, various solvents, surfactants, colorants, and the like.
[0022]
The inhalation fragrance may contain other active ingredients. Examples of other active ingredients include benzyl alcohol, methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole. Such other active ingredients potentiate the antioxidant action and the anti-mental stress action of leaf alcohol and linalool. For example, benzyl alcohol, when contained in the inhalation fragrance, provides a depth in the fragrance. When the inhalation fragrance contains benzyl alcohol, the mixing ratio is preferably 0.001% by mass or more and 0.05% by mass or less based on the total amount of the inhalation fragrance.
[0023]
The inhalation fragrance may be used as it is, or as it is, or as a food flavoring containing a surfactant and a colorant. For example, the inhalation fragrance is sprinkled on a powdered tea, and hot water is poured thereon, whereby a tea having an aroma can be prepared. When the tea is drunk, the components of the inhalation fragrance are taken in by inhalation and thereby exhibit the antioxidant action and the anti-mental stress action.
[0024]
The Japanese Society of Antioxidants defines oxidative stress as difference between an oxidative damage power of active oxygen species generated in an organism and an antioxidant potential of an antioxidant system in the organism . This can be said in other words as follows: a state with an oxidative stress refers to a state where excessive active oxygen species are generated so that the antioxidant system in the organism can not capture them. Experiment 1 and Experiment 2 described later demonstrate that the inhalation fragrance of the present embodiment has an action to ameliorate or prevent the state with oxidative stress.
[0025]
In addition, the case where the oxidative stress is caused by aging and the case where it is caused by exposure to radiation do not make much difference in the oxidative stress which is the qualitative state. Accordingly, the inhalation fragrance of the present embodiment may have antioxidant actions not only against the oxidative stress due to aging or due to exposure to radiation but also against an oxidative stress caused by the other causes such as air pollution, cigarettes, and the like.
[0026]
The invention will be described more specifically below by means of Examples.
Examples [0027]
Production of Inhalation Fragrance
The inhalation fragrance is described in detail in JP-A-2015-109832 published based on a patent application of the present applicant. The brief is described below. Raw tea leaves are steamed in steam at about 100°C for 30 to 120 seconds . The steam is collected and cooled to around 40°C to 60°C to be converted into a liquid, which is taken as a stock solution. The stock solution is extracted with hexane, and thus, an inhalation fragrance having the aforementioned composition, which contains an ethanol as a solvent and is liquid at normal temperature (18°C to 25°C), is obtained.
[0028]
Formulation Examples
Formulation Example 1
Leaf alcohol: 0.02% by mass
Linalool: 0.005% by mass
Ethanol: 99.9% by mass
Water: balance [0029]
Formulation Example 2
Leaf alcohol: 0.2% by mass
Linalool: 0.03% by mass
Ethanol: 99.9% by mass
Water: balance [0030]
Formulation Example 3
Leaf alcohol: 0.5% by mass
Linalool: 0.1% by mass
Benzyl alcohol: 0.001% by mass
Ethanol: 99.2% by mass
Other active ingredients: 0.1% by mass
The other active ingredients include methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole each in an appropriate amount.
Impurities: 0.05% by mass
The main impurities include l-penten-3-ol, heptanal, (Z)-3-hexanol, and octanol.
Water: balance [0031]
Formulation Example 4
Leaf alcohol: 0.5% by mass
Linalool: 0.05% by mass
Benzyl alcohol: 0.05% by mass
Ethanol: 99.2% by mass
Other active ingredients: 0.1% by mass
The other active ingredients include methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole each in an appropriate amount.
Impurities: 0.05% by mass
The main impurities include l-penten-3-ol, heptanal, (Z)-3-hexanol, and octanol.
Water: balance [0032]
Formulation Example 5: Example of Perfume
Leaf alcohol: 0.5% by mass
Linalool: 0.05% by mass
Benzyl alcohol: 0.05% by mass
Ethanol: 97.1% by mass
Other active ingredients: 0.1% by mass
The other active ingredients include methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole each in an appropriate amount.
Impurities: 0.05% by mass
The main impurities include l-penten-3-ol, heptanal, (Z)-3-hexanol, and octanol.
Limonene: 0.2% by weight (as the other fragrance)
Surfactant: 1.8% by weight
Colorant: appropriate amount
Water: balance [0033]
Formulation Example 6: Example of Food Flavoring
Leaf alcohol: 0.5% by mass
Linalool: 0.05% by mass
Benzyl alcohol: 0.05% by mass
Ethanol: 98% by mass
Other active ingredients: 0.1% by mass
The other active ingredients include methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole each in an appropriate amount.
Impurities: 0.05% by mass
The main impurities include l-penten-3-ol, heptanal, (Z)-3-hexanol, and octanol.
Surfactant: 1% by mass
Colorant: appropriate amount
Water: balance [0034]
Experiment about Antioxidant Action
Ten male ICR mice were each placed in a metabolic cage 1, and five mice among them were assigned to a control group and five mice were assigned to an administered group. Fig. 1 is an external view of the metabolic cages 1. As shown in Fig. 1, in the metabolic cage 1, a water supplier 13 and a feed supplier 14 are connected to a main chamber 12 in which a mouse is to be placed. A net 15 is suspended in the main chamber 12 and a mouse is placed on the net 15. An excrement container 16 that separates feces and urine and stores them is connected under the net 15. All experiments were performed at normal temperature .
[0035]
A lid 11 is placed on the main chamber. The lid 11 has a plurality of inhalation holes. Nonwoven fabric is placed on a portion corresponding to the inhalation holes. The inhalation fragrance was added dropwise to the nonwoven fabric and the mouse was exposed thereto. The mouse was thus allowed to take in the inhalation fragrance through spontaneous breathing.
[0036]
Although each of the following experiments was performed using all the Formulation Example 1 to Formulation Example 5, the results of the experiment were almost identical for all the formulation examples. Thus, only the results for Formulation Example 3 are shown.
[0037]
Experiment 1: Validation of Antioxidant Action against Oxidation due to Aging
Onto the nonwoven fabric placed on the lid 11, the inhalation fragrance was added dropwise every day at 20 μΙ/day until the second week after birth of a newborn mouse and at
200 μΐ/day after the second week, while 8-OHdG in urine was measured. No inhalation fragrance was administered to the control mice.
[0038]
8-OHdG (8-hydroxy-2'-deoxyguanosine) , which is a marker of oxidative damage of DNA, is often measured to determine the oxidative stress by active oxygen. A higher oxidative stress results in a larger amount of 8-OHdG in urine. In this experiment, 8-OHdG in urine was measured according to the following procedure.
[0039] μΐ of urine is mixed with 50 μΐ of a diluted liquid containing ribonucleoside 8-OHGuo. After mixing, the supernatant, which is obtained after centrifugal removal of the precipitation, is resolved by column switching high performance liquid chromatography using combined two columns of an anion exchange column and a reverse phase column, and 8-OHdG is measured by an electrochemical detector (Coulochem III manufactured by ESA).
[0040]
Fig. 2 is a graph showing amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) associated with aging in Experiment 2. The abscissa represents a time and the ordinate represents an amount of 8-OHdG.
[0041]
As shown in Fig. 2, the amount of 8-OHdG in urine increased with aging with respect to both the control group shown by white circles and the administered group shown by black squares. However, the rate of increase in the administered group was clearly lower than in the control group with a significant difference at a significance level less than 5%.
[0042]
Experiment 2: Validation of Antioxidant Action against Radiation Exposure Stress
Five ICR mice were assigned to each of the following groups to conduct Comparative Experiment.
• Group 1: control (with no inhalation fragrance administered and with no exposure to radiation) • Group 2: control with a single exposure to 0.5 Gy radiation • Group 3: with the inhalation fragrance administered but with no exposure to radiation • Group 4: with the inhalation fragrance administered and with a single exposure to 0.5 Gy radiation
To the administered group, 200 μΐ of the inhalation fragrance was added dropwise every day on the nonwoven fabric placed on the lid 11 to administer the inhalation fragrance through spontaneous breathing. No inhalation fragrance was administered to the control group.
[0043]
Exposure to radiation was performed by 0.5 Gy whole body exposure at an exposure dose rate of 0.68 Gy/min using an X ray irradiator (MBR-1520 manufactured by Hitachi Engineering and Services).
[0044]
Fig. 3 is a graph showing amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) associated with exposure to radiation in Experiment 2. The abscissa represents a time and the ordinates represents an amount of 8-OHdG.
[0045]
For each group, the amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) were measured for exposure to radiation before administration (week 0 in Fig. 3), for exposure to radiation after administration for 1 week (week in Fig. 3) , and for exposure to radiation after administration for 7 weeks (week 7 in Fig. 3) . The method for measuring the amount of 8-OHdG in urine is the same as in Experiment 1. [0046]
As shown in Fig. 3, the amount of 8-OHdG in urine increased with time with respect to both Group 2 and Group 4 which are exposed to radiation. The amounts of 8-OHdG in urine in Group after 1 weeks and after 7 weeks clearly increased with respect to Group 1 with a significant difference at a significance level less than 5%. However, the amounts of 8-OHdG in urine in Group had no significant differences from those in Group 3 in the case of administration for 1 week and in the case of administration for 7 weeks.
[0047]
Experiment 3: Validation of Anti-mental Stress Action
Five ICR mice were assigned to each of a control group and an administered group. To the administered group, 200 μΐ of the inhalation fragrance was added dropwise every day on the nonwoven fabric placed on the lid 11 to administer the inhalation fragrance through spontaneous breathing. To the control group, no inhalation fragrance was administered. The change in amount of water drunk with time was compared between the groups .
[0048]
Fig. 4 is a graph showing the change in amount of water drunk with time in Experiment 3. As shown in Fig. 4, at the first to the third week after the start of the administration, the amounts of water drunk in the administered group were significantly less than those in the control group with a significance level less than 5%.
[0049]
There is a report that the amount of water drunk by a mouse increases by stress (for example, T. Goto et la., Behavioral Brain Research 270 (2014) 339-348) . Accordingly, it was suggested that administration of the inhalation fragrance has an anti-mental stress action or a relaxation effect.
[0050]
Experiment 4: Additional Test for Validation of Antioxidant Action against Oxidation due to Aging
Five ICR mice were assigned to each of a control group and an administered group. For the administered group, 1 ml of a diluent obtained by diluting the inhalation fragrance with water by a factor of 5 was sprayed on a floor mat in a breeding cage containing a mouse of the administered group every day until the third week and subsequently three times a week. The mouse was thus allowed to take in the inhalation fragrance through spontaneous breathing. For the control group, 1 ml of water was sprayed on a floor mat in a breeding cage containing a mouse of the control group every day until the third week and subsequently three times a week. Then, amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) per day were measured according to the same procedure as in Experiment
1.
[0051]
Fig. 5 is a graph showing amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) associated with aging in Experiment 4. The abscissa represents time and the ordinate represents amount of 8-OHdG.
[0052]
As shown in Fig. 5, the amount of 8-OHdG in urine tends to increase with aging in the control group, whereas the amount of 8-OHdG in urine does not have an increasing tendency in the administered group to which the inhalation fragrance was administered, and at each of 3 week-old and 20-week old, the amount of 8-OHdG in urine in the administered group is significantly less than in the control group at a significance level less than 5%.
[0053]
Experiment 5: Additional Test of Validation of Antioxidant Action against Radiation Exposure Stress
Four to ten C57BL mice were assigned to each of a control group and an administered group. Then, each group was further divided into the following three groups.
(1) Group subjected to no exposure to radiation (2) Group subjected to a whole body exposure to 0.5 Gy radiation once
| (3) Group | subjected to a whole | body | exposure | to | 0.75 Gy |
| radiation | once | ||||
| The | exposure to radiation | was performed | in | the same | |
| manner as | in Experiment 2 . | ||||
| [0054] | |||||
| For | the administered group, | 1 mL | of a diluent | obtained |
by diluting the inhalation fragrance with water by a factor of 5 was sprayed on a floor mat in a breeding cage containing a mouse of the administered group every day for one week before the exposure to radiation. The mouse was thus allowed to take in the inhalation fragrance through spontaneous breathing. For the control, 1 ml of water was sprayed for one week on a floor mat in a breeding cage containing a mouse of the control group .
[0055]
Fig. 6 is a graph showing amounts of 8-OHdG in urine (amounts of 8-OHdG (ng) per mg of creatinine) associated with the exposure to radiation in Experiment 5. The abscissa represents an exposure dose to radiation and the ordinate represents an amount of 8-OHdG. The method for measuring 8-OHdG was the same as in Experiment 1.
[0056]
As shown in Fig. 6, an increased exposure dose to radiation resulted in an increase amount of 8-OHdG in urine in the control group, whereas in the administered group to which the inhalation fragrance was administered, even if the exposure dose to radiation increased, the amount of 8-OHdG in urine increased little as compared with the case with no exposure to radiation. In the group of 0.75 Gy, the amount of 8-OHdG in urine in the administered group was significantly less than that in the control group at a significance level less than 5%.
[0057]
Experiment 6: Comparison in Antioxidant Capacity
Four to ten C57BL mice were assigned to each of a control group and an administered group. Then, each group was further divided into the following two groups.
| (1) Group | subjected to no exposure to | radiation | |||
| (2) Group | subjected to a whole | body | exposure | to | 0.75 Gy |
| radiation | once | ||||
| The | exposure to radiation | was performed | in | the same | |
| manner as | in Experiment 2 . | ||||
| [0058] | |||||
| For | the administered group, | 1 mL | of a diluent | obtained |
by diluting the inhalation fragrance with water by a factor of 5 was sprayed on a floor mat in a breeding cage containing a mouse of the administered group every day for one week before the exposure to radiation. The mouse was thus allowed to take in the inhalation fragrance through spontaneous breathing. For the control group, 1 ml of water was sprayed for one week on a floor mat in a breeding cage containing a mouse of the control group.
[0059]
Then, the antioxidant capacity in serum was measured. The antioxidant capacity in serum was measured using PAO-U manufactured by Japan Institute for the Control of Aging.
[0060]
Fig. 7 is a graph showing measurement results of the antioxidant capacity in serum in Experiment 6. The ordinate represents the measurement results of PAO-U. As shown in Fig. 7, with respect to the groups (1), comparing antioxidant capacity between the control group and the administered group, the antioxidant capacity significantly increased in the administered group as compared with that in the control group at a significance level less than 5%. With respect to the groups (2) subjected to exposure to radiation, the antioxidant capacity in the administered group significantly decreased at a significance level less than 5%.
[0061]
Conclusion
It was found from the above results of Experiment that the inhalation fragrance, when taken in through inhalation, has an antioxidant action against oxidation due to aging and an antioxidant action against radiation exposure stress. It was also found that the inhalation fragrance has the effects even if containing impurities and the other fragrance. It was further found that the inhalation fragrance, when inhaled, has an anti-mental stress action.
[0062]
Although the above Experiments were performed using animals (mice), it is natural that the same effects be achieved on humans.
[0063]
As described above, the inhalation fragrance of the present embodiment contains leaf alcohol and linalool as active ingredients and ethanol as a main solvent. Accordingly, the inhalation fragrance is easily taken in through inhalation. The inhalation fragrance, when taken in through inhalation, exhibits an antioxidant action against oxidation due to aging and an antioxidant action against radiation exposure stress. In addition, the inhalation fragrance, when taken in through inhalation, provides a high anti-mental stress action. Reference Signs List [0064]
1: metabolic cage
| 11: | lid |
| 12 : | main chamber |
| 15: | net |
ABSTRACT
To provide an inhalation fragrance that can be taken in by means other than oral administration.
[Means for Resolution] The inhalation fragrance contains leaf alcohol and linalool, contains ethanol as a main solvent, and is liquid at normal temperature. The leaf alcohol may be contained in an amount of 0.02% by mass or more and 0.5% by mass or less based on the total amount, and the linalool may be contained in an amount of 0.005% by mass or more and 0.1% by mass or less based on the total amount. The inhalation fragrance, when taken in through inhalation, exhibits one or more of an antioxidant action against oxidative stress due to aging and an antioxidant action against oxidative stress due to exposure to radiation. The inhalation fragrance, when taken in through inhalation, exhibits an anti-mental stress action .
Claims (3)
1. A liquid inhalation fragrance to be used for anti-oxidation against oxidative stress, comprising ethanol as a main solvent and following materials derived from tea leaves:
leaf alcohol, linalool, benzyl alcohol, methyl salicylate, geraniol,
2-phenylethanol, β-ionone, (E)-nerolidol, and indole.
2. A liquid inhalation fragrance to be used for anti-oxidation against radiation exposure stress, comprising ethanol as a main solvent and following materials derived from tea leaves:
leaf alcohol, linalool, benzyl alcohol, methyl salicylate, geraniol,
2-phenylethanol, β-ionone, (E)-nerolidol, and indole.
3. The liquid inhalation fragrance according to claim 1 or 2, wherein the leaf alcohol is contained in an amount of 0.02% by mass or more and 0.5% by mass or less based on the total amount, the linalool is contained in an amount of 0.005% by mass or more and 0.1% by mass or less based on the total amount, and benzyl alcohol, methyl salicylate, geraniol, 2-phenylethanol, β-ionone, (E)-nerolidol, and indole are contained in a total amount of 0.001% by mass or more and 0.1% by mass or less based on the total amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019200397A AU2019200397B2 (en) | 2015-09-25 | 2019-01-21 | Inhaling fragrance, perfume, and food flavoring |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015187566A JP2018184346A (en) | 2015-09-25 | 2015-09-25 | Suction flavor, perfume and food product flavor |
| JP2015-187566 | 2015-09-25 | ||
| PCT/JP2016/069931 WO2017051585A1 (en) | 2015-09-25 | 2016-07-05 | Inhaling fragrance, perfume, and food flavoring |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200397A Division AU2019200397B2 (en) | 2015-09-25 | 2019-01-21 | Inhaling fragrance, perfume, and food flavoring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016327484A1 AU2016327484A1 (en) | 2018-05-10 |
| AU2016327484B2 true AU2016327484B2 (en) | 2018-12-06 |
Family
ID=58385999
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016327484A Ceased AU2016327484B2 (en) | 2015-09-25 | 2016-07-05 | Inhaling fragrance, perfume, and food flavoring |
| AU2019200397A Active AU2019200397B2 (en) | 2015-09-25 | 2019-01-21 | Inhaling fragrance, perfume, and food flavoring |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200397A Active AU2019200397B2 (en) | 2015-09-25 | 2019-01-21 | Inhaling fragrance, perfume, and food flavoring |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2018184346A (en) |
| AU (2) | AU2016327484B2 (en) |
| WO (1) | WO2017051585A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022071580A1 (en) * | 2020-10-01 | 2022-04-07 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05230496A (en) * | 1992-02-24 | 1993-09-07 | Nippon Fine Chem Co Ltd | Compound perfume and aromatic composition containing same |
| JPH08113522A (en) * | 1994-10-14 | 1996-05-07 | Earth Chem Corp Ltd | Solubilizer for thermal transpiration perfume and aqueous perfume composition for thermal transpiration |
| JPH08319477A (en) * | 1995-05-27 | 1996-12-03 | Akio Usui | Method for controlling heat generation of heat generating material composition, heat generating material composition, heat generating material, plaster, device for emitting perfume, and device for emitting pesticide or bactericide |
| US20040242452A1 (en) * | 2001-08-08 | 2004-12-02 | Ken Shoji | Perfume composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4381263B2 (en) * | 2004-09-10 | 2009-12-09 | 長谷川香料株式会社 | Production of tea extracts and tea flavorings |
| JP2012139215A (en) * | 2010-12-14 | 2012-07-26 | Fukujuen:Kk | Recovery method of tea leaf flavor composition in tea manufacturing step and tea manufacturing and processing step and manufacturing method of tea beverage using tea leaf flavor composition recovered by the method |
| JP6128562B2 (en) * | 2013-11-05 | 2017-05-17 | 株式会社アクト・フォ | Tea leaf aromatic distillate |
-
2015
- 2015-09-25 JP JP2015187566A patent/JP2018184346A/en active Pending
-
2016
- 2016-07-05 WO PCT/JP2016/069931 patent/WO2017051585A1/en active Application Filing
- 2016-07-05 AU AU2016327484A patent/AU2016327484B2/en not_active Ceased
-
2019
- 2019-01-21 AU AU2019200397A patent/AU2019200397B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05230496A (en) * | 1992-02-24 | 1993-09-07 | Nippon Fine Chem Co Ltd | Compound perfume and aromatic composition containing same |
| JPH08113522A (en) * | 1994-10-14 | 1996-05-07 | Earth Chem Corp Ltd | Solubilizer for thermal transpiration perfume and aqueous perfume composition for thermal transpiration |
| JPH08319477A (en) * | 1995-05-27 | 1996-12-03 | Akio Usui | Method for controlling heat generation of heat generating material composition, heat generating material composition, heat generating material, plaster, device for emitting perfume, and device for emitting pesticide or bactericide |
| US20040242452A1 (en) * | 2001-08-08 | 2004-12-02 | Ken Shoji | Perfume composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018184346A (en) | 2018-11-22 |
| AU2019200397B2 (en) | 2019-08-22 |
| AU2019200397A1 (en) | 2019-02-07 |
| AU2016327484A1 (en) | 2018-05-10 |
| WO2017051585A1 (en) | 2017-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cimino et al. | Essential oils: Pharmaceutical applications and encapsulation strategies into lipid-based delivery systems | |
| Khan et al. | Thymus vulgaris: alternative to antibiotics in poultry feed | |
| Bulotta et al. | Beneficial effects of the olive oil phenolic components oleuropein and hydroxytyrosol: focus on protection against cardiovascular and metabolic diseases | |
| Barocelli et al. | Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil | |
| Ping et al. | Antidiabetic effects of cinnamon oil in diabetic KK-Ay mice | |
| Burton et al. | Dietary luteolin reduces proinflammatory microglia in the brain of senescent mice | |
| Cheng et al. | Evaluation of anxiolytic potency of essential oil and S-(+)-linalool from Cinnamomum osmophloeum ct. linalool leaves in mice | |
| Koutroumanidou et al. | Increased seizure latency and decreased severity of pentylenetetrazol-induced seizures in mice after essential oil administration | |
| CN103442703A (en) | A water soluble composition comprising curcumin having enhanced bioavailability and process thereof | |
| CN1475204A (en) | Medicinal Composition, dry powder vapor, nebula, nebula auxiliary preparation for use through mouth and nose and its preparation method | |
| KR101523820B1 (en) | Pharmaceutical composition for preventing or treating obesity or metabolic disorders comprising Aster glehni extract as an active ingredient | |
| Aqil et al. | Multi-layer polymeric implants for sustained release of chemopreventives | |
| AU2019200397B2 (en) | Inhaling fragrance, perfume, and food flavoring | |
| WO2020202193A1 (en) | Synergistic combination of phytoactives | |
| Cimino et al. | Essential oils: Pharmaceutical applications and encapsulation strategies into lipid-based delivery systems. Pharmaceutics 2021, 13, 327 | |
| Patra et al. | Flavored Food Additives on the Leaves of Piper betle L.: A Human Health Perspective | |
| JP6444583B2 (en) | Oral composition | |
| Lansky et al. | Harmal: The genus peganum | |
| Ullah et al. | Polyphenols as possible alternative agents in chronic fatigue: a review | |
| Sharma et al. | Evaluation of anti-obesity activity of Convolvulus pluricaulis extract | |
| Selvan et al. | Effect of 4-Allyl-2-methoxyphenol (eugenol) on motor co-ordination in subacute restraint stress Induced wistar albino rats | |
| Srivastava et al. | Essential Oils | |
| KR20090112268A (en) | Pharmaceutical composition for treatment and prevention of brain cell damage caused by beta-amyloid containing herb essential oil | |
| CN102860940A (en) | Wrinkle removing nursing compound essential oil | |
| El-Nabarawy et al. | Comparative study of some natural and artificial food coloring agents on depression, anxiety and anti-social behavior in weanling rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |